Notably, sitagliptin, a dipeptidyl peptidase 4 (DPP4) inhibitor, augments CD8+ T cell infiltration in HCC tissues in diabetic individuals, potentially enhancing PD-1 blockade-based immunotherapy in selected HCC patients [195]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.